Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. - Wikidata - wikimedia - TriplyDB

Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.

Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.

http://www.wikidata.org/entity/Q34556770

about

Levels of soluble E-cadherin in breast, gastric, and colorectal cancers Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes Roles for E-cadherin cell surface regulation in cancer Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors.E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition.High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation.Lobular breast cancer: molecular basis, mouse and cellular models.Melatonin: an inhibitor of breast cancer.Enhanced Expression of Integrin αvβ3 Induced by TGF-β Is Required for the Enhancing Effect of Fibroblast Growth Factor 1 (FGF1) in TGF-β-Induced Epithelial-Mesenchymal Transition (EMT) in Mammary Epithelial Cells All-trans-retinoic Acid Modulates the Plasticity and Inhibits the Motility of Breast Cancer Cells: ROLE OF NOTCH1 AND TRANSFORMING GROWTH FACTOR (TGFβ).Effect of Melatonin in Epithelial Mesenchymal Transition Markers and Invasive Properties of Breast Cancer Stem Cells of Canine and Human Cell Lines RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells.miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations.Endothelial cadherins in cancer.Cadherin-mediated cell-cell interactions in normal and cancer cells.Expression of tripartite motif-containing protein 28 in primary breast carcinoma predicts metastasis and is involved in the stemness, chemoresistance, and tumor growth.Positive Quantitative Relationship between EMT and Contact-Initiated Sliding on Fiber-like Tracks.Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers.An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas.Interactions of human MSC with head and neck squamous cell carcinoma cell line PCI-13 reduce markers of epithelia-mesenchymal transition.Suppression of the TGF-β1-induced protein expression of SNAI1 and N-cadherin by miR-199a.Loss of E-cadherin expression is not a prerequisite for c-erbB2-induced epithelial-mesenchymal transition.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.PLC-β2 is modulated by low oxygen availability in breast tumor cells and plays a phenotype dependent role in their hypoxia-related malignant potential.Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis.Autocrine hGH stimulates oncogenicity, epithelial-mesenchymal transition and cancer stem cell-like behavior in human colorectal carcinoma.Overexpression of 14-3-3ζ in lung tissue predicts an improved outcome in patients with lung adenocarcinoma.Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation

P2860

Q27012638-3F87B356-7667-4955-A723-AE474CC649F4 Q28543021-FACD6299-885C-4214-89A9-864FBF34329D Q30275556-BC47FB9A-BDE5-4747-956E-6182EA438F07 Q33690570-6880AE29-32AD-43F8-8B6C-06D5B3894351 Q34037623-B7B2D095-81AF-458B-9EF9-EFC2DD2B07D7 Q34100951-F097B44A-84C3-4212-AFFB-335391AE330F Q34978807-7D926C6F-0188-4C0A-8538-F2CCE336E724 Q35059856-BACB6E27-DAFB-43AA-B242-E378404DE601 Q35689110-F6F59502-7B18-4D85-922F-B281B24B0322 Q35763007-10A7A42B-69B9-4990-8E74-780B488B1040 Q35859452-0A7C1D8C-6373-40DF-9F33-B5743F605612 Q35943145-6172BBDB-A368-4729-92EB-A3F6EB22C67D Q36413997-1E8DE334-0905-47A9-AF85-BAA80E25729E Q36902949-B0CDF9B2-AFDB-43FF-8A26-EAB28FD708CE Q37381612-5CA141AE-9BDD-4712-A508-124E6C8C0C7D Q38195199-4E1CA634-E5F1-4890-84A6-CEEB6176063C Q38637064-619131B5-46CD-42AA-B3E0-AD9B2FB0ED4D Q38708750-2E0565DD-F291-4DF3-8475-E0643E37D216 Q38742408-8E493508-C67E-4DAF-94A7-CCD47AD17B30 Q38819847-995EE3F5-2401-43CF-8EFC-83088BA4D02E Q38824148-CE9C837C-625D-4E43-9FC4-B0BCBA4CDB16 Q38945001-91A17AE1-B316-41B8-BF50-17F6E041E5D1 Q38973907-1F2279FB-9F23-4A82-A0A5-973D4D2B1B3A Q38997298-D2C4159A-963A-45AC-AF24-8D6A8C1C1A4A Q39107981-C43C7564-10FE-4161-BBAC-B5A56C42568D Q40088702-AD8EDFF1-F3C3-48BA-9A12-763F3B9579D6 Q41149484-2313558D-0614-4715-9CB1-588CB5F4156B Q41260173-1D29373B-3FFB-45B5-9205-8DF2EFCD051B Q47107528-759B4231-D9D7-4A5C-9253-F021B34A02AC Q55512817-302B28A6-B42A-4956-843A-0C1D156AC950 Q58721369-7CC0CC28-93FC-4914-A9D0-D13D4D204997

P2860

Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.

http://www.wikidata.org/entity/Q34556770

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@ast

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@en

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@nl

type

label

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@ast

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@en

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@nl

prefLabel

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@ast

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@en

Loss of E-cadherin is not a ne ...... sition in human breast cancer.

@nl

P1433

Q34556770-690B6A28-9158-4E53-93BC-3F0935B8DAE4

P1476

Q34556770-5EF5AE5C-4521-4A4D-B7C1-053B6636B671

P2093

Q34556770-019406CD-666D-4164-ABD6-D880A7F5B6A3

Q34556770-43A37988-6A2E-488A-8401-79CA87B3BD9E

Q34556770-4539A3CA-9100-47F8-A87A-B0C445383CD5

Q34556770-5291B85B-8CFB-4BD3-A257-EB4F08C3FD25

Q34556770-7A060C89-9756-4170-BC96-820F8FB1674D

Q34556770-8D42FBE2-F347-47B4-B6F2-37A8BB2D9914

Q34556770-B8F368FC-8409-4AB9-9672-B406AA953A64

Q34556770-BAC9DBF1-E2FE-472E-9479-882097722FFA

Q34556770-BEB05B33-BF8B-496B-AC8B-68067116307C

Q34556770-C0887D51-3023-4649-8767-F788DDAADDDD

P2860

Q34556770-054DDDC1-1BF9-4DB5-8E2F-FC1A7E2035DB

Q34556770-06CBE890-3C13-4F59-850C-691058C5293A

Q34556770-17BF5682-8259-4BB0-8AD6-0357E062AC49

Q34556770-1AFA4891-8934-46D6-AAD8-08F7DBC24AC4

Q34556770-22CE2B8B-967A-4ABD-B711-F40FD9DEFA86

Q34556770-2A9D066D-6DD6-49F7-BFBF-ED5F950ED17D

Q34556770-2D75E704-CBC9-432D-B9EC-EC17C168DEB0

Q34556770-3AE0BDB9-6DFC-4486-A13B-FD27247ED36D

Q34556770-41E238D2-C70C-4912-8A01-D502CDD3FAEC

Q34556770-4235E4A9-200B-45DE-B532-4BCEF7F6E171

P2888

Q34556770-18CF0FA3-9D16-416E-9C8F-765EFEDD0932

P304

Q34556770-47DB2A93-C430-45E5-BD0C-7751F6E9A0E6

P31

Q34556770-EDD81271-3169-46CE-AD09-F42099A902D1

P356

Q34556770-46A86B11-8606-4AE1-A858-95F65ED3A065

P407

Q34556770-0D77D92D-9042-4166-BE5C-7CD25A72B314

P433

Q34556770-17ED5776-15F5-44EA-9208-8EE04B50304A

P478

Q34556770-97F83EBF-61FB-4736-B98B-541A032EFDD0

P50

Q34556770-16F7FD0F-A4BA-4C36-9438-C47CD1041A7F

Q34556770-AEA11B5A-F59E-4466-97D6-F9E3EA6A078F

Q34556770-C934F661-4067-4F4C-B6B7-0A1A6E689B0B

Q34556770-FA6D856B-B4BB-4980-8B8C-53DB61B84779

P577

Q34556770-6D64C8BD-7F8D-4CF6-89BD-6E89552F3698

P5875

Q34556770-AAD3DFB2-9750-42AC-A334-213F9E6B09F8

P6179

Q34556770-FE24FA69-4863-4FA4-9187-82A9975E48AD

P698

Q34556770-66D01F3C-F916-4752-A5EC-41295E7E6E61

P356

S10549-013-2415-3

P1433

Breast Cancer Research and Treatment

P1476

Loss of E-cadherin is not a ne ...... nsition in human breast cancer

@en

P2093

Alan Chan

http://www.w3.org/2001/XMLSchema#string

Anieta M Sieuwerts

http://www.w3.org/2001/XMLSchema#string

Anouk A J Heine

http://www.w3.org/2001/XMLSchema#string

Jan G M Klijn

http://www.w3.org/2001/XMLSchema#string

John A Foekens

http://www.w3.org/2001/XMLSchema#string

John W M Martens

http://www.w3.org/2001/XMLSchema#string

Justine K Peeters

http://www.w3.org/2001/XMLSchema#string

Leon C Verhoog

http://www.w3.org/2001/XMLSchema#string

Michael A den Bakker

http://www.w3.org/2001/XMLSchema#string

Mieke Schutte

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Significance analysis of microarrays applied to the ionizing radiation response

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

The epithelial-mesenchymal transition generates cells with properties of stem cells

Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

Molecular definition of breast tumor heterogeneity

Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

P2888

s10549-013-2415-3

P304

47-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-013-2415-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P50

Antoinette Hollestelle

Pieter J Westenend

P577

2013-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234824143

http://www.w3.org/2001/XMLSchema#string

P6179

1025356289

http://www.w3.org/2001/XMLSchema#string

P698

23338761

http://www.w3.org/2001/XMLSchema#string